Onxeo announces the great success of its share capital increase with shareholders’ preferential subscription rights
Total demand of Approximately 76.4 million euros, i.e. an oversubscription rate of 216% of the offer Full exercise of the […]
BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma Publishes its first Shareholder Newsletter
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
Positive Phase II preliminary results of Validive® for the prevention of Severe Oral Mucositis in Head and Neck cancer patients
Positive Phase II preliminary results of Validive® For the prevention of Severe Oral Mucositis in Head and Neck cancer patients […]
BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma provides updates on its major achievements and reports 2013 consolidated financial results
2013: Significant progress on key strategic programs • Livatag® phase III (ReLive): European expansion and authorization from the FDA to […]
Publication of the 2013 Registration Document
BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]
BioAlliance Pharma and Topotarget enter into merger agreement to create a leading orphan oncology company
— Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical […]
Quarterly information as of March 31, 2014
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
Definitive Merger Plan between BioAlliance Pharma and Topotarget – Combined Entity to be named Onxeo
DEFINITIVE MERGER PLAN BETWEEN BIOALLIANCE PHARMA AND TOPOTARGET COMBINED ENTITY TO BE NAMED ONXEO — Onxeo expected to have a […]
Registration of “Document E” and clearance of admission prospectus related to the proposed cross-border of Topotarget into BioAlliance Pharma
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
Merger Plan with Topotarget: Pre-approval for the secondary listing of the shares of the merged company on NASDAQ OMX Copenhagen
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma and Topotarget shareholders approve proposed cross-border merger to create Onxeo
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specializing in the development of drugs for orphan oncology diseases, […]
BioAlliance Pharma strengthens its financial resources with the support of its top shareholder
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014 – Final calendar for trading on both Euronext and NASDAQ OMX to be available soon
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, […]
Approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen, Merger exchange to take place on August 5, 2014
Suite à l’annonce conjointe des deux sociétés le 23 juillet 2014, BioAlliance Pharma SA (Euronext Paris – BIO), société innovante […]
Key milestones and consolidated accounts – First six months 2014
Major evolution of the Company, renamed Onxeo, resulting from the merger between BioAlliance Pharma and Topotarget Good progress of the […]
Onxeo attends InvestorDagen 2014, the largest Danish private investor event
Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specialized in the development of drugs for orphan […]
Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance”
Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, […]
Quarterly Information as of September 30, 2014
Quarterly Information as of September 30, 2014 – Effective integration of both entities, BioAlliance Pharma and Topotarget, into newly named […]
Onxeo Launches a Rights Issue With Shareholder Preferential Subscription Rights, for a Maximum Amount of up to €41.6 Million (Including an Extension Clause of €5.3 Million)
Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”), an innovative biopharmaceutical company specialized in the development […]
Onxeo confirms receipt of the $25M milestone payment on Beleodaq®
Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, […]
Onxeo announces positive DSMB recommendation for its Phase III trial with Livatag® in primary liver cancer
Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, […]
Onxeo reaches second milestone of BPIFrance grant dedicated to Livatag® development as part of NICE Consortium
Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, […]
Onxeo strengthens Beleodaq® patent protection in the U.S. until 2027
Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specialized in the development of drugs for orphan […]
BioAlliance Pharma announces the launch of Sitavig® in the United States by its partner Innocutis and the granting of a new U.S. Sitavig® patent
BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]
FDA approval of Beleodaq™ (belinostat)
• Accelerated Approval of Topotarget’s Beleodaq™ for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma • Early […]
Execution of a license agreement with EMS for Sitavig® in Brazil
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma strengthens Livatag® patent protection in Japan until 2032
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
Livatag® receives Fast Track Designation from the FDA for the treatment of primary liver cancer
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma announces major achievements on Validive®: Enrollment completion in the international Phase II trial with Validive® in severe oral mucositis, Presentation of preclinical data at the next ASCO annual meeting
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma announces a new positive DSMB recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma collaborates with Penn Pharma on the industrial development of Validive®
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
Sitavig® Licensing Strategy: Execution of licensing agreement with Innocutis for North America and Positive opinion from French and German Health Authorities for Marketing Authorization
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced major […]
BioAlliance Pharma’s partner, Sosei, announces a partnership with FUJIFILM Pharma for commercialization rights for Loramyc® in Japan
Paris, February 4, 2014 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan […]
Strengthening and extension of the industrial protection of Livatag® until 2031 – First delivery of a new European patent
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced today […]
FDA grants Validive® (clonidine Lauriad®) with a Fast Track Designation for the prevention and treatment of oral mucositis induced by anticancer treatments
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology, announced today that […]